HCV / Hepatitis

Infectious disease pediatrician Sharon Nachman, MD, offers insights on what is already being done in clinical practice with regards to vaccines, the CDC committee's votes on the MMRV and hepatitis b vaccines, and understanding how they will affect these immunizations going forward.

The non-vote leaves the current immunization recommendation in place, but led to further debate amongst the CDC's ACIP panelists on the hepatitis B vaccine as well as questioning the current process of the delivery of data and whether they would be utilizing working groups and grading studies.

The committee voted to change the MMRV vaccine recommendation, left panelists uncertain around a second MMRV immunization vote, and delayed the hepatitis B vaccine vote until Friday.

Vincent Lo Re, MD, MSCE, FISPE, reviews HR-pQCT findings, IL-18 and TNF-α declines, and guidance for clinicians.

At the ICE-HBV Cure Symposium, EBT-107 showed reduced intrahepatic HBV DNA and no increase in chromosomal translocations, supporting a path toward first-in-human testing.

Bluejay Therapeutics’ investigational therapy, brelovitug, offers weekly self-administered injections and will be studied against the only approved treatment outside the US.

This week, people with HIV are living longer on antiretroviral therapy but face elevated comorbidity risks, requiring tailored screening and multidisciplinary care as they age, and more.

A decade-long study finds the ratio independently predicts risk, with patients aged ≥30 facing higher progression rates.

Philippa Easterbrook, MD, MPH, FRCP, explains barriers in primary care, the promise of community models, and how simplified guidelines could expand access to treatment.

Ty Stoner of Walgreens Specialty Pharmacy on navigating barriers, building partnerships, and improving access for vulnerable populations.

Vir initiates phase 2b head-to-head trial of novel combination therapy vs bulevirtide.

This week, from synthetic biosecurity concerns to gaps in maternal hepatitis C screening, rising COVID cases, antimicrobial resistance, fast-tracked CF therapies, and more.

Despite updated guidelines for universal hepatitis C virus screening in pregnancy, testing rates remain well below targets, missing chances to prevent perinatal transmission.

Study reveals notable sex-based disparities in liver complication risk among adults with cirrhosis, particularly in nonviral cases.

The study will examine the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis D virus RNA despite bulevirtide treatment.

Unsaturated fats in vegetable oils help reduce inflammation and modulate organ metabolism, leading to decreased ALT, AST, and TBIL levels.

Global modeling identifies vertical transmission burden and underscores need for maternal screening policies.

First representative data highlight regional and demographic variations, underscoring the need for enhanced vaccination and targeted interventions.

This week, AI speeds antibiotic discovery, Temple’s ID team celebrates tradition, EDs boost Hep C detection, thimerosal exits flu shots, and the pandemic’s silent toll on brain health emerges.

Lin Zhu explains why testing alone will not achieve HCV elimination without better access and integrated care.

This week, the first US study screening hepatitis B and D concurrently found that 2.2% of HBV-positive samples had HDV antibodies, the FDA approved GSK’s Shingrix, and more.

Study findings underscore the cost-effectiveness of more frequent hepatitis C testing among people who inject drugs, compared to less frequent or no testing at all.

Shortening the OraQuick HCV antibody test from 20 to 5 minutes reduced false positives and unnecessary follow-up RNA testing, but detected fewer viremic individuals.

DETECT Hep C trial shows nontargeted testing in emergency departments outperforms risk-based screening, yet treatment follow-through remains low.

Findings from recent studies published in BMC Gastroenterology highlight practical diagnostic tools and novel therapeutic strategies to improve management of chronic hepatitis B.

This week, the ACIP recommends clesrovimab for RSV protection in infants under 8 months without maternal immunity, ASM Microbe talk urges for creative funding solutions amid federal freezes to sustain research and careers, and more.

New longitudinal study findings suggest booster vaccination may not be necessary despite declining antibody levels.

Presented at ASM Microbe 2025, a bioinformatics study highlights 9 human miRNAs capable of binding and potentially inhibiting both hepatitis C and bovine viral diarrhea viruses.

Data from the 2023 Centers for Disease Control and Prevention surveillance report highlight key differences in death rates across states and populations, informing targeted public health efforts.

After initially closing its viral hepatitis and sexually transmitted disease laboratories, the CDC rescinds staff terminations, preserving vital disease surveillance and outbreak response capabilities.